Development, Characterization, and Evaluation of Anti-fungal activity of Nystatin loaded Nanogel

Authors

Amit U. Bindu, Tejas S. Pachpute
Department of Pharmaceutics, Alwar Pharmacy College, Sunrise University, Alwar, Rajasthan, India.

Abstract

Nystatin has been used as a fungal inhibitor. Nystatin is applied topically since the oral method of delivery irritates the gastrointestinal tract and can cause ulcers. The antifungal nanogel used in this study was designed to optimize in-vitro release and in-vivo release investigations while also reducing particle size. Using a homogenization process with carbopol 940 added as a gelling agent, Nystatin nanogels were created, yielding a smooth antifungal nanogel (F1-F6). Fourier transform infrared analysis of antifungal nanogels (F1–F6) revealed no interactions between the medication and excipients. The optimal formulation (F6) produced a high in-vitro release of 84.43% after 8 hours; the resulting values for particle size and zeta- potential were 230 nm and -27 mV, respectively. It was demonstrated by in-vitro release kinetic models that formulation-F6 adheres to high regression coefficient value, r 2 0.9967, and first- order kinetics. The optimal formulation (F6)'s scanning electron microscopy image shows that there is no nanogel breakup. Nystatin was reported to have a differential scanning calorimetry (DSC) thermogram of 166 oC. The physical mixture of carbopol 940 and Eudragit-S 100 was discovered to have a DSC thermogram of 129°C and 218°C. The medication and excipients did not interact, according to the DSC analysis of nanogel (F6). An in-vivo investigation using mice revealed that the optimal formulation, F6, had a superior therapeutic effect for dermatitis. The best formulation, F6, was determined to have improved dermatitis scoring and better in-vitro medication release.